Status:

WITHDRAWN

A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors

Lead Sponsor:

National Cancer Institute (NCI)

Conditions:

Brain Stem Neoplasms

Glioma

Eligibility:

All Genders

1-21 years

Phase:

PHASE1

Brief Summary

Background: \- IMC-A12 is an experimental substance designed to inhibit a protein called Type I Insulin-Like Growth Factor Receptor (IGF-1R), which can be found on cancer cells and can promote cancer...

Detailed Description

Background * IMC-A12 is a fully recombinant IgG1monoclonal antibody to the insulin-like growth factor receptor (IGFR). It acts as an antagonist of IGF-1 and IGF-2 ligand binding and blocks ligand bin...

Eligibility Criteria

Inclusion

  • Eligibility
  • Patients \> 12 months and less than or equal to 21 years of age with a diagnosis and histologic verification (except patients with intrinsic brain stem tumors, optic pathway gliomas or pineal tumors and elevations of serum or CSF alpha-fetoprotein or beta-HCG) of measureable or evaluable relapsed or refractory solid tumors. Current disease state must be one for which there is no known curative therapy, or therapy proven to prolong survival.
  • Must have fully recovered from acute toxic effects from all prior therapy, which has been completed within the specified prior time frame.
  • Have adequate organ function as determined by laboratory evaluation including normal random or fasting blood glucose within the upper normal limits for age and grade \< 2 serum cholesterol and triglyceride levels.
  • Subjects with uncontrolled infection, known type I or type II diabetes mellitus, known bone marrow involvement or who have received prior monoclonal antibody therapy targeting IGF-1R or temsirolimus are not eligible.

Exclusion

    Key Trial Info

    Start Date :

    July 28 2010

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    April 4 2012

    Estimated Enrollment :

    Patients enrolled

    Trial Details

    Trial ID

    NCT01182883

    Start Date

    July 28 2010

    End Date

    April 4 2012

    Last Update

    July 2 2017

    Active Locations (0)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 0 (0 locations)

    No Results Found

    We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

    A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors | DecenTrialz